Communiqués Cognition Therapeutics, Inc.

Actions

CGTX

US19243B1026

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:43:28 18/09/2026			Varia. 5j.	Varia. 1 janv.
1,065 ^USD	+0,47%		+8,20%	-21,48%

07/08	Cognition Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
24/06	Cognition Therapeutics trouve un accord avec la FDA sur le cadre de l’essai de phase 3 pour un traitement de la psychose	MT

Communiqués

08/09	Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference	AQ
06/08	Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update	GL
13/07	Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit	AQ
24/06	Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes	AQ
16/06	Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045	AQ
01/06	Cognition Therapeutics Participating in Upcoming Investor Conferences	AQ
22/05	Cognition Therapeutics Completes Meeting with FDA for Zervimesine in Dementia with Lewy Bodies with Psychosis	AQ
21/05	Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis	AQ
14/05	Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies	AQ
07/05	Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update	GL
07/04	Cognition Therapeutics to Present at Needham Virtual Healthcare Conference	AQ
31/03	Cognition Therapeutics CEO Issues Letter to Shareholders	GL
26/03	Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update	GL
23/03	Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results	AQ
17/03	Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026	AQ
02/03	Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis	AQ
05/02	Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies	AQ
27/01	Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies	AQ
06/01	Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies	AQ
03/12	Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies	AQ
01/12	Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference	AQ
20/11	Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference	AQ
13/11	Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease	AQ
06/11	Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs	GL
03/09/25	Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target	AQ